ASND — Ascendis Pharma A/S

Ascendis Pharma (ASND) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: EUR 247 million, which includes EUR 197 million from YORVIPATH and EUR 44 million from SKYTROFA, alongside EUR 6 million in collaboration revenue.
• Operating Profit: EUR 25 million (10% operating margin), with non-IFRS operating profit at EUR 55 million (22% non-IFRS operating margin).
• Net Profit: EUR 629 million, boosted by a EUR 679 million deferred tax asset recognition. Non-IFRS net profit was EUR 18 million (EUR 0.27 per share).
• Cash Position: EUR 573 million in cash and cash equivalents, following a EUR 60 million impact from a share repurchase program.
• R&D Expenses: EUR 59 million, down from EUR 78 million in Q4 2025, aided by a write-up of YUVIWEL inventory.
• SG&A Expenses: Increased to EUR 145 million from EUR 136 million in Q4 2025 due to global commercial expansion efforts.

2. Strategic Updates and Business Highlights

• Product Approvals: FDA approval of YUVIWEL marks the third product launch in a row for Ascendis, expanding their portfolio in rare endocrine indications.
• Pipeline Development: Over 20 ongoing or planned clinical trials, including 4 new clinical entities in preclinical development.
• YORVIPATH Performance: Continued strong uptake with over 1,000 new patients prescribed in Q1 and a total of over 6,300 patients on therapy.
• Market Expansion: YORVIPATH is available in 35 countries, with full commercial reimbursement in 6 European markets.
• New Product Launches: YUVIWEL launched in early April, with over 60 prescriptions in the first few weeks, indicating strong demand.

3. Forward Guidance and Outlook

• YORVIPATH: Anticipated steady revenue growth in Q2, with expectations to reverse onetime impacts seen in Q1.
• SKYTROFA: Expected stable revenue throughout the year, following a similar seasonal pattern to 2025.
• YUVIWEL: Positive early demand trends noted, with further updates expected in Q2.
• Operating Cash Flow Target: Reaffirmed target of EUR 500 million, with expectations for improved operating margins as revenue scales.

4. Bad News, Challenges, or Points of Concern

• Onetime Impacts: Q1 revenue was affected by a temporary increase in patients on free drug due to reimbursement disruptions and a one-time impact from Europe Direct.
• Competitive Landscape: Concerns regarding potential competition from other treatments in the hypoparathyroidism space, particularly related to a recent Phase III trial by AstraZeneca.
• Reimbursement Challenges: Ongoing complexities in the reimbursement process for YORVIPATH, although improvements in approval rates and timelines were noted.

5. Notable Q&A Insights

• YORVIPATH Sales Breakdown: Analysts sought clarity on U.S. versus ex-U.S. sales, with management indicating that the onetime impacts were primarily localized.
• Reauthorization Rates: Reauthorization rates for YORVIPATH were reported to be consistent with initial patient approvals, indicating a stable demand.
• Patient Demographics: YUVIWEL's initial uptake includes a mix of treatment-naive patients and switches from existing therapies, with ongoing efforts to support patient transitions.
• Retention Rates: High retention rates in clinical trials were highlighted, showcasing patient satisfaction with treatment.
• Capital Allocation Strategy: Focus on R&D investment to sustain long-term growth, with updates expected post-Q2 regarding financial outlook and strategic initiatives.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Ascendis Pharma's Q1 2026 performance and outlook.